drugset / Trial / NCT01271933
Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia. All patients will receive pregabalin; half of the patients will receive placebo at some point in the study.
Timeline
- Start
- 2011-03
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pregabalin | Small molecule | 330 mg | — |
| Subject | Pregabalin | Small molecule | 495 mg | — |